Health Technology Assessment

A summary of OHE’s activity at the 2016 winter HESG meeting, Manchester, 6-8th January.

Professor Weinstein compares the use of cost-per-QALY approaches in the UK and the US. Britain has got it closer to right, but may go a little too far.

This post summarises OHE’s activities at the ISOQOL 22nd Annual Conference in Vancouver, October 2015.

OHE’s Deputy Director Paula Lorgelly will present an OHE Seminar on 14th December 2015 on the topic of HTA decision makers as budget takers and budget makers.

Do members of the general public wish to place greater weight on a unit of health gain for end of life patients than on that for other types of patients?

Multi-indication pricing (MIP) involves setting a different price for each major indication approved for a medicine. We explore the feasibility of implementing MIP in the UK.

This study tests the feasibility of eliciting EQ-5D-5L values from a general public sample in the United Arab Emirates.

This post summarises OHE’s activities at this year’s ISPOR Latin America conference in Santiago, September 2015. Topics include policy options for formulary development in middle-income countries, and role of HTA in definition of health benefit plans.

Recently published in Health Policy is an article by Sarah Karlsberg Schaffer, Jon Sussex, Nancy Devlin and Andrew Walker entitled “Local health care expenditure plans and their opportunity costs”.

A Research Paper on the topic of incorporating life-cycle price modelling into pharmaceutical cost-effectiveness evaluations has just been published by OHE.

Pages

Subscribe to RSS - Health Technology Assessment